Jain et al. reported that Saroglitazar reduces hypertriglyceridemia and improves insulin sensitivity along with β-cell function by reduction in gluco-lipotoxicity and possibly directly through PPAR-γ agonism in patients of T2DM with hypertriglyceridemia24. Here, PPARG is linked to type 2 diabetes mellitus.